NURIX THERAPEUTICS, INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $-57.7M | $34.8M |
| FY2020 | — | $290.3M | $119.4M |
| FY2021 | — | $342.3M | $80.5M |
| FY2022 | — | $303.7M | $64.5M |
| FY2023 | — | $200.5M | $54.6M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $-57.7M | $34.8M |
| FY2020 | — | $290.3M | $119.4M |
| FY2021 | — | $342.3M | $80.5M |
| FY2022 | — | $303.7M | $64.5M |
| FY2023 | — | $200.5M | $54.6M |